|
X-BODY teams up with China-based Hengrui to develop therapeutic antibodies …
pharmabiz.com X-BODY Biosciences, a privately held biotechnology company, has entered into an exclusive alliance with Jiangsu Hengrui Medicine Co., Ltd. (Hengrui), in which Hengrui will develop and commercialize a novel antibody programme generated from X-BODY’s … |
|
Is Chronic Fatigue Syndrome an Autoimmune Disease?
Blogcritics.org (blog) In 2007 Øystein Fluge and Olav Mella, two Norwegian oncologists at Haukeland University Hospital in Bergen, Norway, accidentally discovered that rituximab, a drug employed to treat Hodgkin’s lymphoma (as well as autoimmune disorders such as … |
|
This Week in Biotech
Motley Fool The end of the week also brought good news for Biogen Idec (NASDAQ: BIIB ) investors — as if you haven’t been riding high already from the approval of Tecfidera — when the company announced positive midstage results for Daclizumab for the treatment … |
|
Biogen Hits Primary Endpoints in MS Study
Motley Fool Biotech company Biogen Idec’s (NASDAQ: BIIB ) developmental multiple sclerosis drug daclizumab succeeded in the SELECT phase 2b trial evaluating its safety and effectiveness in treating patients with relapse-remitting MS. The trial results, originally … Biogen Idec Inc. (NASDAQ:BIIB) Jumps over 34% in 3 Months As Positive MS …Galaxy Stocks |
 TopNews Arab Emirates |
Lower Darwen mum calls on government to protect cancer drugs fund
Lancashire Telegraph The Rarer Cancers Foundation said treatments to be removed from the approved list include rituximab, used to treat blood cancers, alemtuzumab, for leukaemia sufferers, and erlotinib, used to treat lung cancer. Chief executive Andrew Wilson said: “The … Cancer patients facing race against clock for drugs in fund ‘betrayal’Telegraph.co.uk The great cancer betrayal: Number of treatments on approved list for patients …Daily Mail |
|
Emergent BioSolutions to Expand Front Line CLL Clinical Trial of TRU-016 and …
EON: Enhanced Online News (press release) “Emergent is pleased with the progress of our Phase 1b study of TRU-016 in combination with rituximab in front line patients with CLL. The strong enrollment and the encouraging early data from this open label study are expected to facilitate an … |
The Wild Story Behind A Promising Experimental Cancer DrugForbesIn 1997, IDEC delivered rituximab, the first monoclonal antibody approved by the FDA for cancer treatment; it is also used for the treatment of rheumatoid arthritis. IDEC merged with Bioge…
 RedOrbit |
Simpler HIV-fighting antibodies could assist vaccine designers
The Verge Powerful HIV-fighting antibodies have long been found in complicated forms that are difficult to implement as vaccines, but researchers have now studied a simpler version of such an antibody and developed a road map to create a vaccine based on it. HIV Vaccine May Come From Our Evolving AntibodiesRedOrbit Anti-HIV Antibodies May Spur AIDS Vaccine DevelopmentTIME Antibodies ‘map’ to vaccine for AIDS foundThe Japan Times Latinos Post –AIDSmeds.com HIV/AIDS Treatment News –Bloomberg all 45 news articles » |
Reducing Relapse with New MS MedicationdailyRxPatients were assigned to take daclizumab or placebo (fake medication) every four weeks for 52 weeks. A total of 208 patients were assigned to 150 mg doses of daclizumab, 209 were assigned to 300 mg doses o…
MarketWatch (press release)OPKO Health Announces Publication of Study Detecting Antibodies in NMO …MarketWatch (press release)MIAMI, Apr 05, 2013 (BUSINESS WIRE) — OPKO Health, Inc. (NYSE:OPK) today announced the publication of a study applying its …